RheumaGen

About:

RheumaGen is a gene-editing technology developing therapeutics to cure rheumatoid arthritis.

Description:

RheumaGen is a gene-editing technology developing therapeutics to cure rheumatoid arthritis. It offers an HLA gene-editing platform that uses stem-cell-enriched blood to alter DNA to suppress the immune system and stop rheumatoid arthritis's abnormal immune response.

Total Funding Amount:

$4.91M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Denver, Colorado, United States

Founded Date:

2019-01-01

Founders:

Number of Employees:

1-10

Last Funding Date:

2024-04-16

IPO Status:

Private

Industries: